Over the past 3 decades, advances in the molecular genetics of thyroid cancer (TC) have
been translated into diagnostic tests, prognostic markers, and therapeutic agents. The main …

Purpose: The determinants of response or resistance to radioiodine (RAI) are unknown. We
aimed to identify genomic and transcriptomic factors associated with structural responses to …

Simple Summary Papillary thyroid cancer (PTC) comprises approximately 80% of all thyroid
malignancies. The field of PTC genetics and cancerogenesis remains undetermined …

Objective: Differentiated thyroid cancer (DTC) is associated with an excellent prognosis, but
patients with distant metastatic DTC have a 10-year disease-specific survival (DSS) of just …

Simple Summary Histopathological diagnosis is prone to significant observer variation in the
diagnosis of papillary thyroid carcinomas (PTCs) due to different thresholds of malignancy …

Genomic and transcriptomic analysis has furthered our understanding of many tumors. Yet,
thyroid cancer management is largely guided by staging and histology, with few molecular …

Tall cell papillary thyroid carcinoma (TC-PTC) is considered adverse histology. However,
previous studies are confounded by inconsistent criteria and strong associations with other …

Background: While the diagnosis of papillary thyroid carcinomas (PTCs) with tall cell
features (PTCtcf) is often made for carcinomas with histological features intermediate …

Simple Summary The BRAFV600E point mutation is the most common driver mutation in
papillary thyroid carcinoma (PTC) and is known to be associated with aggressive clinical …

Abstract Objectives lncRNA ABHD11 antisense RNA 1 (ABHD11-AS1) acts as an oncogene
involved in papillary thyroid carcinoma (PTC) occurrence and progression. ABHD11-AS1 …